

Supporting Information

Structure-Activity Study of Bioisosteric Trifluoromethyl and Pentafluorosulfanyl Indole Inhibitors of the AAA ATPase p97

Celeste Alvarez,^{†,‡} Michelle R. Arkin,[§] Stacie L. Bulfer,[§] Raffaele Colombo,[‡] Marina Kovaliov,[‡] Matthew G. LaPorte,[‡] Chaemin Lim,[‡] Mary Liang,[‡] William J. Moore,[&] Jeffrey R. Neitz,[§] Yongzhao Yan,[‡] Zhizhou Yue,[‡] Donna M. Huryn^{†,‡,*} and Peter Wipf^{†,‡,*}

[†]Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15260; [‡]University of Pittsburgh Chemical Diversity Center, University of Pittsburgh, Pittsburgh, PA 15260; [§]Department of Pharmaceutical Chemistry, Small Molecule Discovery Center, University of California, San Francisco, CA 94158; [&]Leidos Biomedical Research, Inc., P.O. Box B, Frederick, MD 21702, United States

Contents

General Methods	S-2
Experimental Procedures	S-3
<i>tert</i> -Butyl (2-(4-isopropylpiperazin-1-yl)ethyl)(piperidin-4-yl)carbamate (17)	S-3
<i>N</i> -(2-(4-Isopropylpiperazin-1-yl)ethyl)-1-(3-(5-(trifluoromethyl)-1 <i>H</i> -indol-2-yl)phenyl)piperidin-4-amine (12).....	S-4
1-(3-[5-(Pentafluoro- λ^6 -sulfanyl)-1 <i>H</i> -indol-2-yl]phenyl)- <i>N</i> -(2-[4-(propan-2-yl)piperazin-1-yl]ethyl)piperidin-4-amine (13).....	S-6
<i>N</i> -(2-(4-Isopropylpiperazin-1-yl)ethyl)-1-(3-(5-nitro-1 <i>H</i> -indol-2-yl)phenyl)piperidin-4-amine (23)	S-8
<i>N</i> -(2-(4-Isopropylpiperazin-1-yl)ethyl)-1-(3-(5-methyl-1 <i>H</i> -indol-2-yl)phenyl)piperidin-4-amine (24).....	S-11
<i>N</i> -(2-(4-Isopropylpiperazin-1-yl)ethyl)-1-(3-(5-methoxy-1 <i>H</i> -indol-2-yl)phenyl)piperidin-4-amine (25)	S-13
<i>N</i> -(2-(4-Isopropylpiperazin-1-yl)ethyl)-1-(3-(5-(trifluoromethoxy)-1 <i>H</i> -indol-2-yl)phenyl)piperidin-4-amine (26).....	S-14
NMR Spectra.....	S-18

General Methods

All non-aqueous reactions were carried out under a nitrogen atmosphere in oven- or flame-dried glassware unless otherwise noted. Anhydrous tetrahydrofuran and diethyl ether were distilled from sodium benzophenone ketyl; anhydrous dichloromethane and toluene were distilled from CaH₂; alternatively, the same solvents were obtained from a solvent purification system using alumina columns. All other solvents and reagents were used as obtained from commercial sources without further purification unless noted. Reactions were monitored via TLC using 250 μ m pre-coated silica gel 60 F₂₅₄ plates, which were visualized with 254 nm and/or 365 nm UV light and by staining with KMnO₄ (1.5 g KMnO₄, 10 g K₂CO₃, and 1.25 mL 10% NaOH in 200 mL water), cerium molybdate (0.5 g Ce(NH₄)₂(NO₃)₆, 12 g (NH₄)₆Mo₇O₂₄•4H₂O, and 28 mL conc. H₂SO₄ in 235 mL water), or vanillin (6 g vanillin and 1.5 mL conc. H₂SO₄ in 100 mL EtOH). Flash chromatography was performed with SiliCycle silica gel 60 (230-400 mesh) or with ISCO MPLC. ¹H and ¹³C NMR spectra were recorded on Bruker Avance 300, 400, or 500 MHz spectrometers, using the residual solvent as an internal standard. IR spectra were obtained on a Smiths IdentifyIR or PerkinElmer Spectrum 100. HRMS data were obtained on a Thermo Scientific Exactive HRMS coupled to a Thermo Scientific Accela HPLC system using a 2.1 x 50 mm 3.5 μ m Waters XTerra C₁₈ column eluting with MeCN/H₂O containing 0.1% formic acid. Purity of compounds was assessed using the same HPLC system with either the PDA or an Agilent 385 ELSD. All final screening samples passed QC based on >95% purity by LC/MS/ELSD analysis.

Experimental Procedures

tert-Butyl (2-(4-isopropylpiperazin-1-yl)ethyl)(piperidin-4-yl)carbamate (17).

A solution of benzyl 4-oxopiperidine-1-carboxylate (1.54 g, 6.61 mmol), 2-(4-isopropylpiperazin-1-yl)ethan-1-amine¹ (1.03 g, 6.01 mmol), and AcOH (52.2 μ L, 0.902 mmol) in anhydrous CH₂Cl₂ (100 mL) was treated with NaBH(OAc)₃ (1.94 g, 9.02 mmol). The reaction mixture was stirred at room temperature overnight, diluted with CH₂Cl₂ (100 mL), washed with sat. NaHCO₃, brine, dried (Na₂SO₄), and evaporated to give benzyl 4-((2-(4-isopropylpiperazin-1-yl)ethyl)amino)piperidine-1-carboxylate (2.33 g, quant.) as a pale yellow oil that was used without further purification: ¹H NMR (300 MHz, CDCl₃) δ 7.37-7.32 (m, 5 H), 5.12 (s, 2 H), 4.11 (app d, J = 10.3 Hz, 2 H), 2.88 (app t, J = 11.8 Hz, 2 H), 2.74-2.47 (m, 14 H), 1.85 (d, J = 12.6 Hz, 2 H), 1.35-1.22 (m, 2 H), 1.06 (d, J = 6.5 Hz, 6 H).

A solution of benzyl 4-((2-(4-isopropylpiperazin-1-yl)ethyl)amino)piperidine-1-carboxylate (8.34 g, 21.5 mmol) in anhydrous CH₂Cl₂ (350 mL) was treated with Boc₂O (8.43 g, 38.6 mmol). The reaction mixture was stirred at room temperature overnight, diluted with CH₂Cl₂ (350 mL), washed with sat. NaHCO₃, brine, dried (Na₂SO₄), evaporated, and purified by chromatography on SiO₂ (2% MeOH/CH₂Cl₂ with 1% TEA) followed by chromatography on basic Al₂O₃ (0 to 1% MeOH/CH₂Cl₂) to give benzyl 4-((*tert*-butoxycarbonyl)(2-(4-isopropylpiperazin-1-yl)ethyl)amino)piperidine-1-carboxylate (8.08 g, 77%) as a colorless oil: ¹H NMR (400 MHz, CDCl₃) δ 7.38-7.29 (m, 5 H), 5.11 (s, 2 H), 4.26 (bs, 2 H), 4.09 (bs, 1 H), 3.17 (bs, 2 H), 2.78 (bs, 2 H), 2.66-2.40 (m, 11 H), 1.65-1.56 (m, 4 H), 1.45 (s, 9 H), 1.03 (d, J = 6.5 Hz, 6 H).

A solution of benzyl 4-((*tert*-butoxycarbonyl)(2-(4-isopropylpiperazin-1-yl)ethyl)amino)piperidine-1-carboxylate (2.54 g, 5.20 mmol) in THF (120 mL) was treated with 10% Pd/C (0.512 g, 0.480 mmol). The reaction mixture was subjected to 3 cycles of vacuum/hydrogen backfill and stirred for 3 d under a hydrogen

¹ Tapia, I.; Alonso-Cires, L.; Lopez-Tudanca, P. L.; Mosquera, R.; Labeaga, L.; Innerarity, A.; Orjales, A. *J. Med. Chem.* **1999**, *42*, 2870-2880.

atmosphere. The reaction mixture was filtered through a pad of Celite® and concentrated to give *tert*-butyl (2-(4-isopropylpiperazin-1-yl)ethyl)(piperidin-4-yl)carbamate (**17**, 1.80 g, 98%) as a colorless oil: ¹H NMR (300 MHz, CDCl₃) δ 4.01 (bs, 1 H), 3.23 (app t, *J* = 5.4 Hz, 2 H), 3.11 (d, *J* = 11.8 Hz, 2 H), 2.68-2.43 (m, 13 H), 1.68-1.65 (m, 2 H), 1.60-1.52 (m, 2 H), 1.46 (s, 9 H), 1.04 (d, *J* = 6.5 Hz, 6 H); HRMS (ESI) *m/z* calcd for C₁₉H₃₉O₂N₄ [M+H]⁺ 355.3068, found 355.3067.

***N*-(2-(4-Isopropylpiperazin-1-yl)ethyl)-1-(3-(5-(trifluoromethyl)-1H-indol-2-yl)phenyl)piperidin-4-amine (12).**

A solution of 3-bromiodobenzene (**32**, 0.284 g, 1.00 mmol), 5-trifluoromethylindole² (0.155 g, 0.840 mmol), Pd(OAc)₂ (10 mg, 0.04 mmol), bis(diphenylphosphino)methane (17 mg, 0.040 mmol), and KOAc (0.249 g, 2.51 mmol) in deoxygenated water (2 mL) was heated at 110 °C for 24 h, cooled to room temperature, diluted with EtOAc (10 mL) and 1 N HCl (5 mL), and extracted with EtOAc (2 x 10 mL). The combined organic layers were dried (MgSO₄), concentrated, and purified by chromatography on SiO₂ (10% EtOAc/petroleum ether). The residue was recrystallized (hexanes/CH₂Cl₂) to give 2-(3-bromophenyl)-5-(trifluoromethyl)-1H-indole (**16**, 139 mg, 49%) as a colorless solid: ¹H NMR (400 MHz, CDCl₃) δ 8.48 (bs, 1 H), 7.92 (s, 1 H), 7.79 (s, 1 H), 7.56 (d, *J* = 7.6 Hz, 1 H), 7.48 (d, *J* = 7.9 Hz, 1 H), 7.46–7.00 (m, 2 H), 7.36–7.27 (m, 1 H), 6.88 (d, *J* = 1.6 Hz, 1 H).

A solution of 2-(3-bromophenyl)-5-(trifluoromethyl)-1H-indole (**16**, 85 mg, 0.25 mmol), LiHMDS (0.10 g, 0.60 mmol), Pd₂(dba)₃ (5 mg, 0.005 mmol), and CyJohnPhos (7 mg, 0.02 mmol) in anhydrous THF was treated with *tert*-butyl (2-(4-isopropylpiperazin-1-yl)ethyl)(piperidin-4-yl)carbamate (**17**, 0.107 g, 0.300 mmol). The reaction mixture was heated at 55 °C overnight, cooled to room temperature, diluted with sat. NaHCO₃, and extracted with CH₂Cl₂ (3x). The combined organic layers were washed with brine, dried (Na₂SO₄), concentrated, and purified by chromatography on SiO₂ (2% MeOH/CH₂Cl₂ with 0.1% TEA) followed by chromatography on basic Al₂O₃ (CH₂Cl₂) to give *tert*-butyl (2-(4-isopropylpiperazin-

² Walkington, A.; Gray, M.; Hossner, F.; Kitteringham, J.; Voyle, M. *Synth. Commun.* **2003**, *33*, 2229–2233.

1-yl)ethyl)(1-(3-(5-(trifluoromethyl)-1*H*-indol-2-yl)phenyl)piperidin-4-yl)carbamate (35 mg, 0.057 mmol, 23%) as a foam: IR (ATR) 3234, 2963, 2930, 2812, 1685, 1601, 1465, 1330, 1151, 1110, 1051 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 9.19 (s, 1 H), 7.89 (s, 1 H), 7.48 (d, $J = 8.4$ Hz, 1 H), 7.38 (dd, $J = 8.4, 1.2$ Hz, 1 H), 7.31 (t, $J = 8.0$ Hz, 1 H), 7.23 (bs, 1 H), 7.16 (bd, $J = 7.6$ Hz, 1 H), 6.90 (dd, $J = 7.8, 1.0$ Hz, 1 H), 6.84 (d, $J = 1.2$ Hz, 1 H), 4.12 (bs, 1 H), 3.79 (bd, $J = 4.0$ Hz, 2 H), 3.22 (bs, 2 H), 2.82–2.47 (m, 13 H), 1.76–1.75 (m, 3 H), 1.48 (s, 9 H), 1.25–1.22 (m, 1 H), 1.11 (d, $J = 6.0$ Hz, 6 H); HRMS (ESI) m/z calcd for $\text{C}_{34}\text{H}_{47}\text{O}_2\text{N}_5\text{F}_3$ $[\text{M}+\text{H}]^+$ 614.3676, found 614.3678.

A solution of TFA (0.43 mL, 5.7 mmol) and triethylsilane (92 μL , 0.57 mmol) in CH_2Cl_2 (1 mL) was added to a solution of *tert*-butyl (2-(4-isopropylpiperazin-1-yl)ethyl)(1-(3-(5-(trifluoromethyl)-1*H*-indol-2-yl)phenyl)piperidin-4-yl)carbamate (35 mg, 0.057 mmol) in CH_2Cl_2 (0.5 mL). The reaction mixture was stirred under an atmosphere of N_2 at room temperature for 1 h, concentrated, diluted with sat. NaHCO_3 , and extracted with EtOAc (3x). The combined organic layers were washed with brine, dried (Na_2SO_4), concentrated, and purified by chromatography on SiO_2 (7 to 9% MeOH/ CH_2Cl_2 with 0.1% TEA) followed by chromatography on basic Al_2O_3 (0 to 9% MeOH/ CH_2Cl_2) to give *N*-(2-(4-isopropylpiperazin-1-yl)ethyl)-1-(3-(5-(trifluoromethyl)-1*H*-indol-2-yl)phenyl)piperidin-4-amine (**12**, 17 mg, 0.033 mmol, 58%) as a yellow oil: ^1H NMR (500 MHz, CDCl_3) δ 8.83 (s, 1 H), 7.89 (s, 1 H), 7.44 (d, $J = 8.5$ Hz, 1 H), 7.40 (dd, $J = 8.5, 1.0$ Hz, 1 H), 7.33–7.30 (m, 1 H), 7.22 (app s, 1 H), 7.11 (d, $J = 7.5$ Hz, 1 H), 6.93 (dd, $J = 8.3, 2.3$ Hz, 1 H), 6.84 (d, $J = 1.5$ Hz, 1 H), 3.74 (app d, $J = 12.5$ Hz, 2 H), 2.85 (td, $J = 12.0, 1.8$ Hz, 2 H), 2.78 (t, $J = 6.3$ Hz, 2 H), 2.68–2.49 (m, 13 H), 2.01 (bd, $J = 12.0$ Hz, 2 H), 1.54 (qd, $J = 11.6, 3.1$ Hz, 2 H), 1.05 (d, $J = 6.5$ Hz, 6 H); ^{13}C NMR (125 MHz, CDCl_3) δ 152.2, 140.6, 138.1, 132.7, 129.9, 129.3, 128.7, 125.5 (q, $J_{\text{CF}} = 271.0$ Hz), 122.7 (q, $J_{\text{CF}} = 31.6$ Hz), 118.9 (q, $J_{\text{CF}} = 3.4$ Hz), 118.3 (q, $J_{\text{CF}} = 4.2$ Hz), 116.5, 113.6, 111.2, 100.5, 58.1, 55.2, 54.6, 53.7, 48.9, 48.6, 43.6, 32.7, 18.8; ^{19}F NMR (376 MHz, CDCl_3) δ -60.4; HRMS (ESI) m/z calcd for $\text{C}_{29}\text{H}_{39}\text{N}_5\text{F}_3$ $[\text{M}+\text{H}]^+$ 514.3152, found 514.3154.

***N*-2-(4-isopropylpiperazin-1-yl)ethyl)-1-(3-(5-(pentafluoro- λ^6 -sulfanyl)-1H-indol-2-yl)phenyl)piperidin-4-amine (13).**

A suspension of 1-bromo-3-(dimethoxymethyl)benzene³ (**18**, 0.19 g, 0.82 mmol), **17** (0.32 g, 0.90 mmol) and K₃PO₄ (0.27 g, 1.2 mmol) in dry dioxane (2.5 mL) was degassed for 40 min by bubbling argon, then Pd₂(dba)₃ (8 mg, 0.008 mmol) and CyJohnPhos (12 mg, 0.032 mmol) were added. The flask was sealed and the reaction mixture was heated at 110 °C for 10 h, diluted with sat. NaHCO₃ and extracted with EtOAc (3x). The combined organic layers were washed with brine, dried (Na₂SO₄), and concentrated. The residue was dissolved in acetone (27 mL) and H₂O (3 mL) and treated with TsOH•H₂O (0.48 g, 2.5 mmol) at rt for 3 h, then diluted with sat. Na₂CO₃ and extracted with EtOAc (3x). The combined organic layers were washed with brine, dried (Na₂SO₄), and concentrated. The residue was purified by chromatography on SiO₂ (95:5 to 85:15 CH₂Cl₂/MeOH) to give *tert*-butyl (1-(3-formylphenyl)piperidin-4-yl)(2-(4-isopropylpiperazin-1-yl)ethyl)carbamate (**19**, 0.32 g, 0.70 mmol, 85% for two steps) as a pale yellow viscous oil: IR (ATR) 2961, 2931, 2808, 1685, 1595, 1450, 1365, 1175, 1145, 776 cm⁻¹; ¹H NMR (500 MHz, CD₂Cl₂) δ 9.97 (s, 1 H), 7.44 (t, *J* = 7.9 Hz, 2 H), 7.32 (d, *J* = 7.4 Hz, 1 H), 7.23 (dd, *J* = 8.2, 2.4 Hz, 1 H), 4.09 (t, *J* = 1.9 Hz, 1 H), 3.87 (d, *J* = 12.5 Hz, 2 H), 3.23 (s, 2 H), 2.88 (t, *J* = 11.6 Hz, 2 H), 2.70-2.45 (m, 11 H), 1.90-1.80 (m, 4 H), 1.48 (s, 9 H), 1.06 (d, *J* = 6.5 Hz, 6 H); ¹³C NMR (125 MHz, CD₂Cl₂) δ 192.6, 155.1, 151.7, 137.5, 129.7, 122.0, 120.9, 115.4, 79.3, 58.3, 54.5, 49.1, 48.5, 40.6, 29.9, 28.2, 18.2; HRMS (ESI) *m/z* calcd for C₂₆H₄₃O₃N₄ [M+H]⁺ 459.3330, found 459.3329.

A solution of 1-nitro-4-(pentafluoro- λ^6 -sulfanyl)benzene (**20**, 1.0 g, 4.0 mmol) and ((chloromethyl)sulfonyl)benzene (**21**, 0.77 g, 4.0 mmol) in DMF (4.0 mL) was added dropwise to a solution of *t*-BuOK (1.6 g, 14 mmol) in DMF (10 mL) at -30 °C. The reaction mixture was stirred for 30 min at -30 °C, quenched by addition of aq HCl (30 mL, 1 M), and extracted with CH₂Cl₂ (3x). The combined organic layers were washed with brine, dried (Na₂SO₄), and concentrated. The crude residue was purified by chromatography on SiO₂ (75:25 hexanes/EtOAc) to afford

³ Kumar, R.; Chakraborti, A. K. *Tetrahedron Lett.* **2005**, *46*, 8319-8323.

pentafluoro(4-nitro-3-((phenylsulfonyl)methyl)phenyl)- λ^6 -sulfane⁴ (1.4 g, 3.4 mmol, 86%) as a pale yellow solid: ¹H NMR (400 MHz, CDCl₃) δ 8.12 (d, *J* = 8.9 Hz, 1 H), 7.95 (dd, *J* = 8.9, 2.3 Hz, 1 H), 7.74-7.69 (m, 4 H), 7.56 (t, *J* = 7.8 Hz, 2 H), 4.98 (s, 2 H); ¹³C NMR (100 MHz, CDCl₃) δ 155.8 (quintuplet, *J*_{CF} = 19.7), 150.6, 137.4, 134.6, 131.91, 131.86, 131.82, 129.6, 128.4, 127.97, 127.93, 127.88, 126.1, 124.5, 58.4.

A suspension of pentafluoro(4-nitro-3-((phenylsulfonyl)methyl)phenyl)- λ^6 -sulfane (1.4 g, 3.5 mmol) and 10% Pd/C (0.11 g, 0.10 mmol) in EtOH (100 mL) was treated with H₂ (balloon, 1 atm) at room temperature for 4 h. The mixture was filtered on Celite® and concentrated to afford a pale yellow solid. The solid was suspended in Et₂O and filtered. The residue was washed with cold Et₂O to give 4-(pentafluoro- λ^6 -sulfanyl)-2-((phenylsulfonyl)methyl)aniline (**22**, 0.5 g) as a white-pale yellow solid. More material was collected from concentration of the mother liquor as a pale yellow solid (0.7 g). The solids were combined to give 4-(pentafluoro- λ^6 -sulfanyl)-2-((phenylsulfonyl)methyl)aniline (**22**, 1.2 g, 3.5 mmol, quant) that was used in the next step without further purification: ¹H NMR (400 MHz, MeOD) δ 7.79-7.71 (m, 3 H), 7.68 (dd, *J* = 9.1, 2.6 Hz, 1 H), 7.59 (t, *J* = 7.8 Hz, 2 H), 7.39 (d, *J* = 9.1 Hz, 1 H), 7.06 (d, *J* = 2.5 Hz, 1 H), 4.58 (s, 2 H).

A suspension of 4-(pentafluoro- λ^6 -sulfanyl)-2-[(phenylsulfonyl)methyl]aniline (**22**, 0.20 g, 0.54 mmol), aldehyde **19** (0.49 g, 1.1 mmol), and MgSO₄ (0.32 g, 2.7 mmol) in acetic acid (2 mL) was heated at 75 °C for 14 h, concentrated, basified with NaHCO₃ and extracted with EtOAc (3x). The combined organic layers were washed with brine, dried (Na₂SO₄) and concentrated. The residue was dissolved in dry DMSO (4 mL) and added to a suspension of powdered KOH (0.15 g, 2.7 mmol) in dry DMSO (2 mL). The reaction mixture was stirred at rt for 90 min, then acidified to pH 8 with sat. NH₄Cl, and extracted with EtOAc (3x). The combined organic layers were washed with brine, dried (Na₂SO₄) and concentrated. The crude residue was purified by chromatography on SiO₂ (7:3, EtOAc/MeOH) to provide *tert*-butyl (2-(4-isopropylpiperazin-1-yl)ethyl)(1-(3-(5-(pentafluoro- λ^6 -sulfanyl)-1*H*-indol-2-yl)phenyl)piperidin-4-yl)carbamate (0.030 g, 0.045 mmol, 8%) as a pale yellow

⁴ Iakobson, G.; Pošta, M.; Beier, P. *Synlett* **2013**; 24, 855-859.

foam: ^1H NMR (400 MHz, CDCl_3) δ 9.33 (s, 1 H), 8.07 (d, $J = 1.8$ Hz, 1 H), 7.59 (dd, $J = 9.0, 2.1$ Hz, 1 H), 7.41 (d, $J = 8.9$ Hz, 1 H), 7.35 (t, $J = 7.9$ Hz, 1 H), 7.23 (s, 1 H), 7.17 (d, $J = 7.6$ Hz, 1 H), 6.94 (d, $J = 7.7$ Hz, 1 H), 6.88 (d, $J = 0.7$ Hz, 1 H), 3.82-3.79 (m, 2 H), 3.26 (t, $J = 1.1$ Hz, 2 H), 2.79-2.51 (m, 13 H), 1.79 (s, 4 H), 1.51 (s, 9 H), 1.08 (d, $J = 6.5$ Hz, 6 H).

A solution of trifluoroacetic acid (1 mL) in CH_2Cl_2 (1 mL) was added to a solution of *tert*-butyl (2-(4-isopropylpiperazin-1-yl)ethyl)(1-(3-(5-(pentafluoro- λ^6 -sulfanyl)-1*H*-indol-2-yl)phenyl)piperidin-4-yl)carbamate (0.025 g, 0.037 mmol) in CH_2Cl_2 (1 mL). The reaction mixture was stirred under N_2 at room temperature for 1 h, concentrated, diluted with NaHCO_3 , extracted with EtOAc (3x), washed with brine, dried (Na_2SO_4) and concentrated. The crude residue was purified by chromatography on SiO_2 (100:8:1 to 100:15:1, $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{NEt}_3$). Purified fractions were concentrated and subsequently filtered through basic Al_2O_3 (100:0 then 100:10, $\text{CH}_2\text{Cl}_2/\text{MeOH}$) to provide *N*-(2-(4-isopropylpiperazin-1-yl)ethyl)-1-(3-(5-(pentafluoro- λ^6 -sulfanyl)-1*H*-indol-2-yl)phenyl)piperidin-4-amine (**13**, 0.013 g, 0.023 mmol, 61%) as a white foam: IR (ATR) 3147, 2923, 2852, 2815, 1603, 1458, 1383, 1148, 839, 809 cm^{-1} ; ^1H NMR (400 MHz, MeOD) δ 8.05 (d, $J = 2.0$ Hz, 1 H), 7.55 (dd, $J = 9.0, 2.1$ Hz, 1 H), 7.48 (d, $J = 9.0$ Hz, 1 H), 7.43 (s, 1 H), 7.34-7.29 (m, 2 H), 6.99-6.96 (m, 2 H), 3.82 (d, $J = 12.6$ Hz, 2 H), 2.85-2.76 (m, 4 H), 2.67-2.51 (m, 13 H), 2.03 (d, $J = 11.7$ Hz, 2 H), 1.54 (dq, $J = 11.8, 3.2$ Hz, 2 H), 1.09 (d, $J = 6.5$ Hz, 6 H); ^{13}C NMR (100 MHz, MeOD) δ 152.0, 146.8, 146.7, 146.5, 141.5, 137.8, 132.5, 129.3, 127.9, 118.5, 118.4, 118.3, 118.2, 116.6, 116.3, 113.3, 110.1, 99.6, 57.0, 54.8, 54.5, 52.7, 42.4, 31.4, 17.3; HRMS (ESI) m/z calcd for $\text{C}_{28}\text{H}_{39}\text{N}_5\text{F}_5\text{S}$ $[\text{M}+\text{H}]^+$ 572.2841, found 572.2836.

***N*-(2-(4-Isopropylpiperazin-1-yl)ethyl)-1-(3-(5-nitro-1*H*-indol-2-yl)phenyl)piperidin-4-amine (23).**

A solution of phenylhydrazine (**27**, 1.80 g, 16.6 mmol) and 3'-bromoacetophenone (**15**, 3.31 g, 16.6 mmol) in EtOH (100 mL) was treated with AcOH (0.050 mL, 0.86 mmol). The mixture was heated at reflux for 2 h under nitrogen, and then concentrated. The residue was recrystallized from hexanes/EtOAc (4:1) and filtered

to afford (*E*)-1-(1-(3-bromophenyl)ethylidene)-2-phenylhydrazine as a pale yellow solid (4.30 g, 14.9 mmol, 90%). This compound was quite unstable and was used immediately for the next conversion.

A suspension of P₂O₅ (12.8 g, 45.1 mmol) and concentrated H₃PO₄ (8 mL) was heated at 100 °C under nitrogen until it formed a clear solution. The temperature was increased to 120 °C and (*E*)-1-(1-(3-bromophenyl)ethylidene)-2-phenylhydrazine (2.00 g, 6.90 mmol) was added in one portion. The reaction mixture was stirred for 1 h at 120 °C, cooled to room temperature, and quenched with crushed ice and water to obtain a white suspension. The solid was filtered, dried on the filter for 15 min, dissolved in Et₂O, dried (Na₂SO₄) and concentrated to afford 2-(3-bromophenyl)-1*H*-indole (**28**, 1.70 g, 6.25 mmol, 90%) as a pale yellow solid: Mp 153-154 °C; IR (ATR) 3430, 1562, 1439, 1420, 1346, 1230, 1073, 1051, 776, 712, 664 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 8.26 (bs, 1 H), 7.80 (t, *J* = 2.0 Hz, 1 H), 7.65 (dd, *J* = 8.0, 0.5 Hz, 1 H), 7.57 (ddd, *J* = 7.8, 1.6, 1.0 Hz, 1 H), 7.45 (ddd, *J* = 8.0, 1.9, 1.0 Hz, 1 H), 7.40 (dd, *J* = 8.0, 0.5 Hz, 1 H), 7.30 (t, *J* = 8.0 Hz, 1 H), 7.23 (ddd, *J* = 8.1, 7.1, 1.1 Hz, 1 H), 7.15 (ddd, *J* = 7.9, 7.1, 0.9 Hz, 1 H), 6.84 (dd, *J* = 2.0, 1.0 Hz, 1 H); ¹³C NMR (125 MHz, CDCl₃) δ 137.0, 136.2, 134.4, 130.52, 130.49, 129.1, 128.1, 123.7, 123.2, 122.9, 120.9, 120.5, 111.0, 101.0; HRMS (ESI) *m/z* calcd for C₁₄H₁₁NBr [M+H]⁺ 272.0069, found 272.0069.

A suspension of 2-(3-bromophenyl)-1*H*-indole (**28**, 5.49 g, 20.2 mmol) in concentrated sulfuric acid (120 mL) at 5 °C was treated dropwise over 30 min with a cold (5 °C) solution of sodium nitrate (1.82 g, 21.4 mmol) in concentrated sulfuric acid (60 mL). The mixture was stirred for 15 min, and then poured onto crushed ice. The yellow precipitate was filtered, dissolved in EtOAc (400 mL), washed with H₂O (3 x 100 mL), sat. NaHCO₃ (2 x 50 mL) and brine, dried (Na₂SO₄), filtered and concentrated. The give crude product (5.53 g) was suspended in MeOH (350 mL), stirred overnight and filtered to afford 2-(3-bromophenyl)-5-nitro-1*H*-indole (4.18 g, 13.2 mmol, 65%) as a bright yellow solid: ¹H NMR (300 MHz, DMSO-*d*₆) δ 12.37 (s, 1 H), 8.55 (d, *J* = 2.1 Hz, 1 H), 8.14 (t, *J* = 1.8 Hz, 1 H), 8.03 (dd, *J* = 8.9, 2.3 Hz, 1 H), 7.93 (ddd, *J* = 7.8, 1.6, 1.1 Hz, 1 H), 7.61-7.56 (m, 2 H), 7.47 (t, *J* = 7.8 Hz, 1 H), 7.30

(d, $J = 1.5$ Hz, 1 H); HRMS (ESI) m/z calcd for $C_{14}H_{10}O_2N_2Br$ $[M+H]^+$ 316.9920, found 316.9918.

A suspension of 2-(3-bromophenyl)-5-nitro-1*H*-indole (0.15 g, 0.47 mmol), and LiHMDS (0.061 mg, 1.4 mmol) in dry deoxygenated THF (1.5 mL) was treated with **17** (0.20 g, 0.57 mmol). The solution was purged with argon for 20 min and treated with $Pd_2(dba)_3$ (0.009 g, 0.01 mmol) and CyJohnPhos (0.013 g, 0.038 mmol). The reaction mixture was heated at 70-75 °C for 24 h in a sealed tube, quenched with sat. $NaHCO_3$ (2 mL) and extracted with EtOAc (3 x 3 mL). The combined organic layers were washed with brine, dried (Na_2SO_4) and evaporated. The residue was purified by chromatography on SiO_2 , (10 to 20% MeOH/ CH_2Cl_2) to give *tert*-butyl (2-(4-isopropylpiperazin-1-yl)ethyl)(1-(3-(5-nitro-1*H*-indol-2-yl)phenyl)piperidin-4-yl)carbamate (0.13 g, 0.31 mmol, 45%) as a yellowish foam: 1H NMR (400 MHz, $CDCl_3$) δ 9.84 (bs, 1 H), 8.54 (d, $J = 2.0$ Hz, 1 H), 8.05 (dd, $J = 8.8, 2.4$ Hz, 1 H), 7.42 (d, $J = 8.8$ Hz, 1 H), 7.30 (t, $J = 7.8$ Hz, 1 H), 7.20-7.16 (m, 2 H), 6.94-6.83 (m, 2 H), 4.06 (bs, 1 H), 3.80-3.60 (m, 2 H), 3.22 (bs, 2 H), 2.70-2.44 (m, 14 H), 1.82-1.61 (m, 4 H), 1.49 (s, 9 H), 1.04 (d, $J = 6.4$ Hz, 6 H); HRMS (ESI) m/z calcd for $C_{33}H_{47}O_4N_6$ $[M+H]^+$ 591.3653, found 591.3654.

A solution of TFA (0.14 mL, 1.9 mmol) in CH_2Cl_2 (0.5 mL) was treated with *tert*-butyl (2-(4-isopropylpiperazin-1-yl)ethyl)(1-(3-(5-nitro-1*H*-indol-2-yl)phenyl)piperidin-4-yl)carbamate (0.020 g, 0.033 mmol) in CH_2Cl_2 (0.5 mL) and stirred for 1.5 h. The reaction mixture was concentrated, diluted with sat. $NaHCO_3$, and extracted with EtOAc (3 x 2 mL). The combined organic layers were washed with brine, dried (Na_2SO_4), filtered, and evaporated. The residue was purified by chromatography on SiO_2 , (5 to 10% MeOH/ CH_2Cl_2 with 0.1% Et_3N) followed by filtration through a plug of basic Al_2O_3 (0 to 10% MeOH/ CH_2Cl_2) to give *N*-(2-(4-isopropylpiperazin-1-yl)ethyl)-1-(3-(5-nitro-1*H*-indol-2-yl)phenyl)piperidin-4-amine (**23**, 0.006 g, 0.01 mmol, 36%) as a yellow foam: IR (ATR, neat) 2932, 2823, 2106, 1660, 1601, 1508, 1472, 1465, 1457, 1327, 1294, 1178, 1070, 753 cm^{-1} ; 1H NMR (500 MHz, acetone- d_6) δ 8.55 (d, $J = 2.5$ Hz, 1 H), 8.03 (dd, $J = 9.0, 2.5$ Hz, 1 H), 7.56 (d, $J = 9.0$ Hz, 1 H), 7.48 (t, $J = 1.8$ Hz, 1 H), 7.35-7.29 (m, 2 H), 7.16 (d, $J = 1.0$ Hz, 1 H), 7.00 (ddd, $J = 7.8, 2.5, 1.4$ Hz, 1 H), 3.79-3.75 (m, 2 H), 2.90 (td, $J = 11.9, 2.1$ Hz, 2 H), 2.78-2.71 (m, 6 H),

2.67-2.57 (m, 3 H), 2.48-2.41 (m, 10 H), 1.99-1.95 (m, 2 H), 1.50-1.43 (m, 2 H), 0.98 (d, $J = 6.5$ Hz, 6 H); ^{13}C NMR (125 MHz, acetone- d_6) δ 152.3, 142.4, 141.8, 140.1, 132.0, 129.7, 128.5, 116.84, 116.77, 116.1, 115.9, 112.8, 111.2, 100.7, 58.2, 54.6, 54.0, 53.7, 48.5, 47.6, 43.5, 32.4, 17.9; HRMS (ESI) m/z calcd for $\text{C}_{28}\text{H}_{39}\text{O}_2\text{N}_6$ $[\text{M}+\text{H}]^+$ 491.3129, found 491.3126.

***N*-(2-(4-Isopropylpiperazin-1-yl)ethyl)-1-(3-(5-methyl-1H-indol-2-yl)phenyl)piperidin-4-amine (24).**

A solution of 3-bromoacetophenone (2.00 g, 10.0 mmol), p-toluidine (1.29 g, 12.1 mmol), and TsOH \cdot H $_2$ O (17 mg, 0.10 mmol) in toluene (50 mL) was heated overnight under Dean-Stark conditions. The reaction mixture was cooled to room temperature, concentrated, and purified by chromatography on SiO $_2$ (0 to 5% EtOAc/hexanes) to provide (*E*)-1-(3-bromophenyl)-*N*-(p-tolyl)ethan-1-imine as a yellow oil (1.10 g, 3.82 mmol, 38%) that was used without further purification.

A solution of (*E*)-1-(3-bromophenyl)-*N*-(p-tolyl)ethan-1-imine (0.246 g, 0.854 mmol), Pd(OAc) $_2$ (18 mg, 0.080 mmol), and Cu(OAc) $_2\cdot$ H $_2$ O (514 mg, 2.57 mmol) in DMSO (3.0 mL) was heated at 90 °C for 5 h, cooled to room temperature, and diluted with EtOAc and H $_2$ O. The layers were separated and the aqueous layer was back-extracted with EtOAc. The combined organic layers were dried (NaSO $_4$) and concentrated. The residue was absorbed onto SiO $_2$ and purified by chromatography on SiO $_2$ (ISCO-Rf, 0 to 20% EtOAc/hexanes) followed by trituration with Et $_2$ O/hexanes (1/1) to give 2-(3-bromophenyl)-5-methyl-1H-indole (**30**, 0.156 g, 0.545 mmol, 64%) as an off white solid: Mp 189-190 °C; IR (ATR) 3428, 1575, 1450, 1420, 1215, 1077, 798, 767, 667 cm^{-1} ; ^1H NMR (500 MHz, CDCl $_3$) δ 8.20 (bs, 1 H), 7.79 (t, $J = 2.0$ Hz, 1 H), 7.56 (d, $J = 7.5$ Hz, 1 H), 7.43-7.41 (m, 2 H), 7.31-7.27 (m, 2 H), 7.04 (dd, $J = 1.0, 8.0$ Hz, 1 H), 6.75 (d, $J = 1.0$ Hz, 1 H), 2.45 (s, 3 H); ^{13}C NMR (125 MHz, CDCl $_3$) δ 136.2, 135.3, 134.6, 130.5, 130.3, 129.7, 129.3, 127.9, 124.5, 123.5, 123.1, 120.5, 110.6 (2C), 21.4; HRMS (ESI) m/z calcd for $\text{C}_{15}\text{H}_{13}\text{NBr}$ $[\text{M}+\text{H}]^+$ 286.0226, found 286.0224.

A solution of 2-(3-bromophenyl)-5-methyl-1H-indole (**30**, 0.143 g, 0.501 mmol), LiHMDS (0.201 g, 1.20 mmol), Pd $_2$ (dba) $_3$ (9 mg, 0.01 mmol), and CyJohnPhos (14

mg, 0.040 mmol) in anhydrous THF was treated with *tert*-butyl (2-(4-isopropylpiperazin-1-yl)ethyl)(piperidin-4-yl)carbamate (**17**, 0.213 g, 0.601 mmol). The reaction mixture was heated at 75 °C overnight, cooled to room temperature, diluted with sat. NaHCO₃, and extracted with CH₂Cl₂ (3x). The combined organic layers were washed with brine, dried (Na₂SO₄), evaporated, and purified by chromatography on SiO₂ (2 to 7% MeOH/CH₂Cl₂) to provide *tert*-butyl (2-(4-isopropylpiperazin-1-yl)ethyl)(1-(3-(5-methyl-1*H*-indol-2-yl)phenyl)piperidin-4-yl)carbamate (0.124 g, 0.222 mmol, 44%) as a foam: IR (ATR) 3303, 2963, 2930, 2809, 1685, 1663, 1599, 1465, 1450, 1174, 1146, 1010, 775 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.96 (s, 1 H), 7.39 (s, 1 H), 7.27-7.24 (m, 2 H), 7.20 (bs, 1 H), 7.13 (d, *J* = 7.2 Hz, 1 H), 6.99 (dd, *J* = 8.0, 0.8 Hz, 1 H), 6.82 (bd, *J* = 7.2 Hz, 1 H), 6.70 (s, 1 H), 4.10 (bs, 1 H), 3.70 (m, 2 H), 3.23 (bs, 2 H), 2.68-2.44 (m, 16 H), 1.72 (bs, 4 H), 1.51 (s, 9 H), 1.04 (d, *J* = 6.4 Hz, 6 H); ¹³C NMR (100 MHz, CDCl₃) δ 155.5, 151.7, 138.6, 135.2, 133.5, 129.6, 129.5, 129.1, 123.6, 120.1, 116.7, 116.0, 113.6, 110.6, 99.2, 79.9, 54.5, 53.8, 49.6, 49.5, 48.6, 39.8, 30.0, 28.5, 21.5, 18.5; HRMS (ESI) *m/z* calcd for C₃₄H₅₀O₂N₅ [M+H]⁺ 560.3959, found 560.3932.

A solution of TFA (2.35 g, 20.4 mmol) in CH₂Cl₂ (1 mL) was added to a solution of *tert*-butyl (2-(4-isopropylpiperazin-1-yl)ethyl)(1-(3-(5-methyl-1*H*-indol-2-yl)phenyl)piperidin-4-yl)carbamate (0.114 g, 0.204 mmol) in CH₂Cl₂ (0.5 mL). The reaction mixture was stirred under an atmosphere of N₂ at room temperature for 1 h, concentrated, diluted with sat. NaHCO₃, and extracted with EtOAc (3x). The combined organic layers were washed with brine, dried (Na₂SO₄), concentrated, and purified by chromatography on SiO₂ (7 to 9% MeOH/CH₂Cl₂ with 0.1% TEA) followed by filtration on basic Al₂O₃ (CH₂Cl₂/MeOH, 100:0 to 100:10) to provide *N*-(2-(4-isopropylpiperazin-1-yl)ethyl)-1-(3-(5-methyl-1*H*-indol-2-yl)phenyl)piperidin-4-amine (**24**, 68 mg, 0.15 mmol, 73%) as a yellow foam: IR (ATR) 2930, 2924, 2811, 1599, 1457, 1448, 1379, 1344, 1189, 1176, 1144, 1117, 982, 775, 734 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.52 (s, 1 H), 7.39 (d, *J* = 0.7 Hz, 1 H), 7.30-7.26 (m, 2 H), 7.21 (t, *J* = 1.9 Hz, 1 H), 7.10 (ddd, *J* = 7.6, 1.4, 0.8 Hz, 1 H), 7.01-6.98 (ddd, *J* = 8.0, 1.6, 0.4 Hz, 1 H), 6.88 (dd, *J* = 8.0, 2.1 Hz, 1 H), 6.70 (dd, *J* = 2.1, 0.8 Hz, 1 H), 3.73 (app d, *J* = 12.6 Hz, 2 H), 2.86-2.76 (m, 4 H), 2.68-2.48 (m, 12 H), 2.44

(s, 3 H), 2.00 (dd, $J = 12.6, 2.2$ Hz, 2 H), 1.53 (dq, $J = 11.5, 3.0$ Hz, 2 H), 1.05 (d, $J = 6.5$ Hz, 6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 152.1, 138.8, 135.2, 133.5, 129.7, 129.6, 129.3, 123.8, 120.3, 116.4, 115.9, 113.5, 110.6, 99.4, 58.1, 55.2, 54.6, 53.6, 48.8, 48.7, 43.5, 32.7, 21.6, 18.8; HRMS (ESI) m/z calcd for $\text{C}_{29}\text{H}_{42}\text{N}_5$ $[\text{M}+\text{H}]^+$ 460.3435, found 460.3434.

***N*-(2-(4-Isopropylpiperazin-1-yl)ethyl)-1-(3-(5-methoxy-1H-indol-2-yl)phenyl)piperidin-4-amine (25).**

A solution of 3-bromiodobenzene (**32**, 0.283 g, 1.00 mmol), 5-methoxyindole (**31**, 0.147 g, 1.00 mmol), $\text{Pd}(\text{OAc})_2$ (12 mg, 0.050 mmol), bis(diphenylphosphino)methane (20 mg, 0.05 mmol), and KOAc (0.297 g, 3.00 mmol) in deoxygenated water (2 mL) was heated at 110 °C for 24 h, cooled to room temperature, diluted with ethyl acetate (10 mL) and 1 N HCl (5 mL), and extracted with ethyl acetate (2 x 10 mL). The combined organic layers were dried (MgSO_4), evaporated, and purified by chromatography on SiO_2 (10% EtOAc/hexanes) followed by recrystallization from hexanes and CH_2Cl_2 to give 2-(3-bromophenyl)-5-methoxy-1H-indole (**33**, 0.133 g, 0.440 mmol, 44%) as a white solid: ^1H NMR (300 MHz, CDCl_3) δ 8.20 (bs, 1 H), 7.77 (s, 1 H), 7.55 (app d, $J = 7.7$ Hz, 1 H), 7.43 (app d, $J = 8.1$ Hz, 1 H), 7.30 (m, 2 H), 7.08 (d, $J = 2.3$ Hz, 1 H), 6.88 (dd, $J = 8.8, 2.4$ Hz, 1 H), 6.76 (d, $J = 1.5$ Hz, 1 H), 3.87 (s, 3 H); HRMS (ESI) m/z calcd for $\text{C}_{15}\text{H}_{13}\text{ONBr}$ $[\text{M}+\text{H}]^+$ 302.0175, found 302.0174.

A solution of **33** (76 mg, 0.25 mmol), K_3PO_4 (82 mg, 0.38 mmol), $\text{Pd}_2(\text{dba})_3$ (5 mg, 0.005 mmol), CyJohnPhos (7 mg, 0.02 mmol) in anhydrous and deoxygenated dioxane (1 mL) in a 2-5 mL conical sealed vessel was degassed by bubbling argon for 5 min. The reaction mixture was treated with *tert*-butyl (2-(4-isopropylpiperazin-1-yl)ethyl)(piperidin-4-yl)carbamate (**17**, 0.106 g, 0.300 mmol) in dry dioxane (1.5 mL) and degassed for 15 min. The vessel was sealed and heated at 110 °C for 11 h in a Biotage Initiator microwave reactor, cooled to room temperature, diluted with sat. NaHCO_3 , and extracted with CH_2Cl_2 (3x). The combined organic layers were washed with brine, dried (Na_2SO_4), evaporated, and purified by chromatography on SiO_2 (2% MeOH/ CH_2Cl_2 and 0.1% TEA) followed by

chromatography on basic Al₂O₃ (CH₂Cl₂) to give *tert*-butyl (2-(4-isopropylpiperazin-1-yl)ethyl)(1-(3-(5-methoxy-1*H*-indol-2-yl)phenyl)piperidin-4-yl)carbamate (46 mg, 0.080 mmol, 32%) as a yellow oil: ¹H NMR (400 MHz, CDCl₃) δ 8.76 (s, 1 H), 7.28-7.25 (m, 2 H), 7.18 (br s, 1 H), 7.12 (d, *J* = 7.6 Hz, 1 H), 7.07 (d, *J* = 2.2 Hz, 1 H), 6.85-6.81 (m, 2 H), 6.71 (d, *J* = 1.2 Hz, 1 H), 4.11 (br s, 1 H), 3.85 (s, 3 H), 3.74-3.72 (m, 2 H), 3.29-3.19 (m, 2 H), 2.71-2.45 (m, 13 H), 1.76-1.72 (m, 3 H), 1.48 (s, 9 H), 1.05 (d, *J* = 6.5 Hz, 6 H); ¹³C NMR (100 MHz, CDCl₃) δ 155.5, 154.4, 151.8, 139.3, 133.5, 132.1, 129.7, 116.7, 116.1, 113.6, 112.4, 111.8, 102.2, 99.6, 80.0, 55.9, 49.6, 48.6, 30.11, 30.09, 28.6, 18.6.

A solution of TFA (0.599 mL, 7.99 mmol) and triethylsilane (0.129 mL, 0.799 mmol) in CH₂Cl₂ (1 mL) was added to a solution of *tert*-butyl (2-(4-isopropylpiperazin-1-yl)ethyl)(1-(3-(5-methoxy-1*H*-indol-2-yl)phenyl)piperidin-4-yl)carbamate (46 mg, 0.080 mmol) in CH₂Cl₂ (0.5 mL). The reaction mixture was stirred under an atmosphere of N₂ at room temperature for 2 h, evaporated, diluted with sat. NaHCO₃, and extracted with EtOAc (3x). The combined organic layers were washed with brine, dried (Na₂SO₄), evaporated, and purified by chromatography on SiO₂ (7 to 9% MeOH/CH₂Cl₂ with 0.1% TEA) followed by chromatography on basic Al₂O₃ (0 to 9% MeOH/CH₂Cl₂) to give *N*-(2-(4-isopropylpiperazin-1-yl)ethyl)-1-(3-(5-methoxy-1*H*-indol-2-yl)phenyl)piperidin-4-amine (**25**, 20 mg, 0.041 mmol, 51%) as a yellow oil: IR (ATR) 3221, 2924, 2818, 1577, 1452, 1881, 1381, 1204, 1176, 1146, 1114, 839, 775 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.74 (bs, 1 H), 7.29 (m, 2 H), 7.21 (app t, *J* = 1.9 Hz, 1 H), 7.11 (app d, *J* = 7.8 Hz, 1 H), 7.07 (d, *J* = 2.3 Hz, 1 H), 6.87 (dd, *J* = 8.1, 2.1 Hz, 1 H), 6.83 (dd, *J* = 8.8, 2.4 Hz, 1 H), 6.71 (app d, *J* = 1.0 Hz, 1 H), 4.01 (bs, 2 H), 3.85 (s, 3 H), 3.72 (app d, *J* = 12.6 Hz, 2 H), 2.84-2.51 (m, 16 H), 2.00 (m, 3 H), 1.56 (qd, *J* = 11.6, 3.0 Hz, 2 H), 1.06 (d, *J* = 6.5 Hz, 6 H); ¹³C NMR (100 MHz, CDCl₃) δ 154.5, 152.0, 139.5, 133.5, 132.2, 129.8, 116.6, 116.0, 113.5, 112.4, 111.8, 102.3, 99.7, 57.4, 56.0, 55.0, 54.7, 53.1, 48.67, 48.54, 43.0, 32.1, 18.5; HRMS (ESI) *m/z* calcd for C₂₉H₄₂ON₅ [M+H]⁺ 476.3384, found 476.3383.

***N*-(2-(4-Isopropylpiperazin-1-yl)ethyl)-1-(3-(5-(trifluoromethoxy)-1*H*-indol-2-yl)phenyl)piperidin-4-amine (26).**

A solution of 3-bromoacetophenone (**15**, 1.00 g, 5.02 mmol), 4-(trifluoromethoxy)aniline (1.07 g, 6.04 mmol), and TsOH•H₂O (8.7 mg, 0.046 mmol) in toluene (50 mL) was heated under Dean-Stark conditions overnight. The reaction mixture was cooled to room temperature, concentrated, and purified by chromatography on SiO₂ (0 to 5% EtOAc/hexanes) to give (*E*)-1-(3-bromophenyl)-N-(4-(trifluoromethoxy)phenyl)ethan-1-imine as a yellow oil (0.91 g, 2.5 mmol, 51%): ¹H NMR (400 MHz, CDCl₃) δ 8.14 (s, 1 H), 7.88-7.86 (m, 1 H), 7.62-7.59 (m, 1 H), 7.32 (td, *J* = 7.6, 0.4 Hz, 1 H), 7.21 (app d, *J* = 8.8 Hz, 2 H), 6.81-6.77 (m, 2 H), 2.22 (s, 3 H).



A solution of (*E*)-1-(3-bromophenyl)-N-(4-(trifluoromethoxy)phenyl)ethan-1-imine (75 mg, 0.21 mmol), Pd(OAc)₂ (5 mg, 0.02 mmol), and TBAB (0.13 g, 0.40 mmol) in DMSO (1 mL) in a Schlenk tube was purged, filled with oxygen and heated at 60 °C for 24 h. The reaction mixture was cooled to room temperature, diluted with ethyl acetate (5 mL), and filtered through SiO₂. The filtrate was washed with 1 M NaHSO₃, concentrated and purified by chromatography on SiO₂ (30% CH₂Cl₂/hexanes) to give 2-(3-bromophenyl)-5-(trifluoromethoxy)-1*H*-indole (**35**, 62 mg, 0.17 mmol, 83%): ¹H NMR (400 MHz, CDCl₃) δ 8.36 (bs, 1 H), 7.78 (s, 1 H), 7.55 (d, *J* = 7.6 Hz, 1 H), 7.48-7.46 (m, 2 H), 7.35 (d, *J* = 8.8 Hz, 1 H), 7.31 (app t, *J* = 8.0 Hz, 1 H), 7.09 (d, *J* = 8.8 Hz, 1 H), 6.81 (s, 1 H); ¹³C NMR (100 MHz, CDCl₃) δ 143.7, 138.2, 135.3, 134.0, 131.1, 130.7, 129.3, 128.3, 123.9, 123.4, 120.9 (q, *J*_{CF} = 255.3 Hz), 116.9, 113.3, 111.7, 101.3; HRMS (ESI) *m/z* calcd for C₁₅H₁₀ONBrF₃ [M+H]⁺ 355.9892, found 355.9891.


A solution of **35** (89.1 mg, 0.250 mmol), K₃PO₄ (82 mg, 0.39 mmol), Pd₂(dba)₃ (4.70 mg, 0.005 mmol), and CyJohnPhos (7.20 mg, 0.020 mmol) in anhydrous and deoxygenated dioxane (1 mL) in a 2-5 mL conical sealed vial was degassed by bubbling argon for 5 min. The reaction mixture was treated with a solution of *tert*-butyl (2-(4-isopropylpiperazin-1-yl)ethyl)(piperidin-4-yl)carbamate (**17**, 0.106 g, 0.299 mmol) in dry dioxane (1.5 mL) and degassed for 15 min. The vial was sealed and heated at 110 °C for 11 h in a Biotage Initiator microwave reactor, cooled to room temperature, diluted with sat. NaHCO₃, and extracted with CH₂Cl₂ (3x). The organic layers were combined, washed with brine, dried (Na₂SO₄), evaporated, and purified by chromatography on SiO₂ (2% MeOH/CH₂Cl₂ with 0.1% TEA) followed by

chromatography on basic Al₂O₃ (CH₂Cl₂) to give *tert*-butyl (2-(4-isopropylpiperazin-1-yl)ethyl)(1-(3-(5-(trifluoromethoxy)-1*H*-indol-2-yl)phenyl)piperidin-4-yl)carbamate (46 mg, 0.073 mmol, 29%) as a light yellow oil: IR (ATR) 3266, 2969, 2961, 2952, 2933, 2928, 2818, 2810, 1681, 1664, 1601, 1478, 1465, 1450, 1413, 1383, 1366, 1346, 1329, 1301, 1253, 1217, 1152, 1010, 1003, 995, 973, 895, 867 cm⁻¹; ¹H NMR (400 MHz, acetone-d₆) δ 10.47 (s, 1 H), 6.97-6.93 (m, 3 H), 6.80-6.76 (m, 2 H), 6.52 (d, *J* = 8.8 Hz, 1 H), 6.45-6.43 (m, 2 H), 3.40 (d, *J* = 12.0 Hz, 2 H), 2.72 (bs, 2 H), 2.48 (bs, 2 H), 2.29 (app t, *J* = 11.6 Hz, 2 H), 1.93-1.89 (m, 9 H), 1.52 (app s, 1 H), 1.42 (bs, 2 H), 1.24 (bs, 2 H), 0.93 (s, 9 H), 0.43 (d, *J* = 6.4 Hz, 6 H); ¹³C NMR (100 MHz, acetone-d₆) δ 155.6, 152.8, 143.7, 141.9, 136.6, 133.6, 130.5, 130.3, 129.1, 128.4, 121.8 (q, *J*_{CF} = 253.2 Hz), 117.0, 116.7, 116.0, 113.8, 113.1, 112.8, 100.1, 79.5, 54.9, 54.8, 50.0, 49.3, 28.7, 18.7; HRMS [ESI] *m/z* calcd for C₃₄H₄₇O₃N₅F₃ [M+H]⁺ 630.3626, found 630.3628.

A solution of TFA (0.50 mL) and triethylsilane (0.10 mL, 0.64 mmol) in CH₂Cl₂ (1 mL) was added to a solution of *tert*-butyl (2-(4-isopropylpiperazin-1-yl)ethyl)(1-(3-(5-(trifluoromethoxy)-1*H*-indol-2-yl)phenyl)piperidin-4-yl)carbamate (40 mg, 0.064 mmol) in CH₂Cl₂ (0.5 mL). The reaction mixture was stirred under an atmosphere of N₂ at room temperature for 1 h, concentrated, diluted with sat. NaHCO₃, and extracted with EtOAc (3x). The combined organic layers were washed with brine, dried (Na₂SO₄), concentrated, and purified by chromatography on SiO₂ (7 to 9% MeOH/CH₂Cl₂ with 0.1% TEA) followed by chromatography on basic Al₂O₃ (0 to 9% MeOH/CH₂Cl₂) to give *N*-(2-(4-isopropylpiperazin-1-yl)ethyl)-1-(3-(5-(trifluoromethoxy)-1*H*-indol-2-yl)phenyl)piperidin-4-amine (**26**, 15 mg, 0.028 mmol, 45%) as a light yellow foam: IR (ATR) 2975, 2818, 1670, 1458, 1254, 1199, 1174, 1130, 829, 800, 783, 719 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 9.02 (s, 1 H), 7.45 (d, *J* = 1.2 Hz, 1 H), 7.36 (d, *J* = 8.8 Hz, 1 H), 7.30 (app t, *J* = 7.6 Hz, 1 H), 7.24 (app t, *J* = 1.6 Hz, 1 H), 7.14-7.11 (m, 1 H), 7.03 (ddd, *J* = 8.8, 2.4, 0.8 Hz, 1 H), 6.90 (ddd, *J* = 8.4, 2.4, 0.8 Hz, 1 H), 6.77 (app d, *J* = 1.2 Hz, 1 H), 3.74 (app d, *J* = 12.8 Hz, 2 H), 2.86-2.52 (m, 16 H), 2.01 (dd, *J* = 12.7, 2.3 Hz, 2 H), 1.59 (qd, *J* = 12.8, 4.0 Hz, 2 H), 1.08 (d, *J* = 6.4 Hz, 6 H); ¹³C NMR (100 MHz, CDCl₃) δ 152.0, 143.4, 140.7, 135.2, 133.0, 129.9, 129.5, 121.0 (q, *J*_{CF} = 255.2 Hz), 116.7, 116.4, 116.1, 113.7, 112.9, 111.6, 100.1, 57.1,



55.2, 55.0, 52.9, 48.5, 43.0, 31.9, 18.4; HRMS [ESI] m/z calcd for $C_{29}H_{39}ON_5F_3$ $[M+H]^+$
530.3101, found 530.3100.






8.06
8.05
7.57
7.56
7.54
7.54
7.49
7.47
7.43
7.34
7.32
7.31
7.29
7.29
6.99
6.98
6.96

3.83
3.80
3.85
2.81
2.79
2.77
2.76
2.67
2.66
2.64
2.62
2.62
2.61
2.57
2.54
2.53
2.51
2.04
2.01
1.59
1.58
1.56
1.55
1.53
1.52
1.50
1.49
1.10
1.08






152.02
146.84
146.68
146.53
141.51
137.83
132.49
129.34
127.93
118.48
118.44
118.40
118.34
118.31
118.28
118.24
118.19
116.60
116.28
113.32
110.16
99.56

57.02
54.83
54.52
52.72


42.37


31.43


17.31



ppm 200 180 160 140 120 100 80 60 40 20 0







8.522
7.396
7.394
7.304
7.284
7.278
7.264
7.260
7.257
7.219
7.214
7.209
7.110
7.108
7.107
7.105
7.091
7.089
7.088
7.086
7.010
7.009
7.006
7.005
6.990
6.989
6.986
6.985
6.896
6.891
6.877
6.871
6.708
6.706
6.701

3.741
3.710
2.858
2.853
2.828
2.823
2.798
2.789
2.773
2.757
2.660
2.643
2.638
2.627
2.621
2.611
2.601
2.585
2.574
2.539
2.524
2.508
2.492
2.484
2.444
2.021
2.016
1.989
1.984
1.578
1.569
1.547
1.541
1.520
1.513
1.491
1.482
1.466
1.044

